Advanced Search
Display options
Filter resources
Text Availability
Article type
Publication date
Species
Language
Sex
Age
Showing 1 to 12 of 53 entries
Sorted by: Best Match Show Resources per page
Medical therapy of ulcerative proctitis and proctosigmoiditis, including refractory disease.

Inflammatory bowel diseases

Bitton A, Peppercorn MA.
PMID: 23282392
Inflamm Bowel Dis. 1995;1(3):207-19.

No abstract available.

Cite
Bitton A, Peppercorn MA. Medical therapy of ulcerative proctitis and proctosigmoiditis, including refractory disease. Inflamm Bowel Dis. 1995;1(3):207-19
Bitton, A., & Peppercorn, M. A. (1995). Medical therapy of ulcerative proctitis and proctosigmoiditis, including refractory disease. Inflammatory bowel diseases, 1(3), 207-19.
Bitton, A, and Peppercorn, M A. "Medical therapy of ulcerative proctitis and proctosigmoiditis, including refractory disease." Inflammatory bowel diseases vol. 1,3 (1995): 207-19.
Bitton A, Peppercorn MA. Medical therapy of ulcerative proctitis and proctosigmoiditis, including refractory disease. Inflamm Bowel Dis. 1995;1(3):207-19. PMID: 23282392.
Copy Download .nbib Format: NLM
Is there hope for Crohn's disease patients with anorectal/vaginal fistulas?.

Inflammatory bowel diseases

Greenberg HL, Peppercorn MA.
PMID: 23282758
Inflamm Bowel Dis. 1997;3(2):176. doi: 10.1097/00054725-199706000-00037.

No abstract available.

Cite
Greenberg HL, Peppercorn MA. Is there hope for Crohn's disease patients with anorectal/vaginal fistulas?. Inflamm Bowel Dis. 1997;3(2):176doi: 10.1097/00054725-199706000-00037.
Greenberg, H. L., & Peppercorn, M. A. (1997). Is there hope for Crohn's disease patients with anorectal/vaginal fistulas?. Inflammatory bowel diseases, 3(2), 176. https://doi.org/10.1097/00054725-199706000-00037
Greenberg, H L, and Peppercorn, M A. "Is there hope for Crohn's disease patients with anorectal/vaginal fistulas?." Inflammatory bowel diseases vol. 3,2 (1997): 176. doi: https://doi.org/10.1097/00054725-199706000-00037
Greenberg HL, Peppercorn MA. Is there hope for Crohn's disease patients with anorectal/vaginal fistulas?. Inflamm Bowel Dis. 1997;3(2):176. doi: 10.1097/00054725-199706000-00037. PMID: 23282758.
Copy Download .nbib Format: NLM
Antibiotics are effective therapy for Crohn's disease.

Inflammatory bowel diseases

Peppercorn MA.
PMID: 23282879
Inflamm Bowel Dis. 1997;3(4):318-9.

No abstract available.

Cite
Peppercorn MA. Antibiotics are effective therapy for Crohn's disease. Inflamm Bowel Dis. 1997;3(4):318-9
Peppercorn, M. A. (1997). Antibiotics are effective therapy for Crohn's disease. Inflammatory bowel diseases, 3(4), 318-9.
Peppercorn, M A. "Antibiotics are effective therapy for Crohn's disease." Inflammatory bowel diseases vol. 3,4 (1997): 318-9.
Peppercorn MA. Antibiotics are effective therapy for Crohn's disease. Inflamm Bowel Dis. 1997;3(4):318-9. PMID: 23282879.
Copy Download .nbib Format: NLM
Early palliative care in cancer treatment: rationale, evidence and clinical implications.

Therapeutic advances in medical oncology

Howie L, Peppercorn J.
PMID: 24179486
Ther Adv Med Oncol. 2013 Nov;5(6):318-23. doi: 10.1177/1758834013500375.

Patients with advanced cancer often experience symptoms of disease and treatment that contribute to distress and diminish their quality of life (QOL). Care that is aimed at control of these symptoms, whether or not the patient is undergoing ongoing...

Cite
Howie L, Peppercorn J. Early palliative care in cancer treatment: rationale, evidence and clinical implications. Ther Adv Med Oncol. 2013;5(6):318-23doi: 10.1177/1758834013500375.
Howie, L., & Peppercorn, J. (2013). Early palliative care in cancer treatment: rationale, evidence and clinical implications. Therapeutic advances in medical oncology, 5(6), 318-23. https://doi.org/10.1177/1758834013500375
Howie, Lynn, and Peppercorn, Jeffrey. "Early palliative care in cancer treatment: rationale, evidence and clinical implications." Therapeutic advances in medical oncology vol. 5,6 (2013): 318-23. doi: https://doi.org/10.1177/1758834013500375
Howie L, Peppercorn J. Early palliative care in cancer treatment: rationale, evidence and clinical implications. Ther Adv Med Oncol. 2013 Nov;5(6):318-23. doi: 10.1177/1758834013500375. PMID: 24179486; PMCID: PMC3799294.
Copy Download .nbib Format: NLM
Secreted Amyloid Precursor Protein-Alpha Promotes Arc Protein Synthesis in Hippocampal Neurons.

Frontiers in molecular neuroscience

Livingstone RW, Elder MK, Barrett MC, Westlake CM, Peppercorn K, Tate WP, Abraham WC, Williams JM.
PMID: 31474829
Front Mol Neurosci. 2019 Aug 14;12:198. doi: 10.3389/fnmol.2019.00198. eCollection 2019.

Secreted amyloid precursor protein-α (sAPPα) is a neuroprotective and memory-enhancing molecule, however, the mechanisms through which sAPPα promotes these effects are not well understood. Recently, we have shown that sAPPα enhances cell-surface expression of glutamate receptors. Activity-related cytoskeletal-associated protein...

Cite
Livingstone RW, Elder MK, Barrett MC, et al. Secreted Amyloid Precursor Protein-Alpha Promotes Arc Protein Synthesis in Hippocampal Neurons. Front Mol Neurosci. 2019;12:198doi: 10.3389/fnmol.2019.00198.
Livingstone, R. W., Elder, M. K., Barrett, M. C., Westlake, C. M., Peppercorn, K., Tate, W. P., Abraham, W. C., & Williams, J. M. (2019). Secreted Amyloid Precursor Protein-Alpha Promotes Arc Protein Synthesis in Hippocampal Neurons. Frontiers in molecular neuroscience, 12198. https://doi.org/10.3389/fnmol.2019.00198
Livingstone, Rhys W, et al. "Secreted Amyloid Precursor Protein-Alpha Promotes Arc Protein Synthesis in Hippocampal Neurons." Frontiers in molecular neuroscience vol. 12 (2019): 198. doi: https://doi.org/10.3389/fnmol.2019.00198
Livingstone RW, Elder MK, Barrett MC, Westlake CM, Peppercorn K, Tate WP, Abraham WC, Williams JM. Secreted Amyloid Precursor Protein-Alpha Promotes Arc Protein Synthesis in Hippocampal Neurons. Front Mol Neurosci. 2019 Aug 14;12:198. doi: 10.3389/fnmol.2019.00198. eCollection 2019. PMID: 31474829; PMCID: PMC6702288.
Copy Download .nbib Format: NLM
Financial Distress, Use of Cost-Coping Strategies, and Adherence to Prescription Medication Among Patients With Cancer.

Journal of oncology practice

Zullig LL, Peppercorn JM, Schrag D, Taylor DH, Lu Y, Samsa G, Abernethy AP, Zafar SY.
PMID: 29431038
J Oncol Pract. 2013 Nov;9(6):60s-63s. doi: 10.1200/JOP.2013.000971.

The authors found that cost-related medication nonadherence was prevalent among patients with cancer who sought financial assistance.

Cite
Zullig LL, Peppercorn JM, Schrag D, et al. Financial Distress, Use of Cost-Coping Strategies, and Adherence to Prescription Medication Among Patients With Cancer. J Oncol Pract. 2013;9(6):60s-63sdoi: 10.1200/JOP.2013.000971.
Zullig, L. L., Peppercorn, J. M., Schrag, D., Taylor, D. H., Lu, Y., Samsa, G., Abernethy, A. P., & Zafar, S. Y. (2013). Financial Distress, Use of Cost-Coping Strategies, and Adherence to Prescription Medication Among Patients With Cancer. Journal of oncology practice, 9(6), 60s-63s. https://doi.org/10.1200/JOP.2013.000971
Zullig, Leah L, et al. "Financial Distress, Use of Cost-Coping Strategies, and Adherence to Prescription Medication Among Patients With Cancer." Journal of oncology practice vol. 9,6 (2013): 60s-63s. doi: https://doi.org/10.1200/JOP.2013.000971
Zullig LL, Peppercorn JM, Schrag D, Taylor DH, Lu Y, Samsa G, Abernethy AP, Zafar SY. Financial Distress, Use of Cost-Coping Strategies, and Adherence to Prescription Medication Among Patients With Cancer. J Oncol Pract. 2013 Nov;9(6):60s-63s. doi: 10.1200/JOP.2013.000971. PMID: 29431038; PMCID: PMC3825170.
Copy Download .nbib Format: NLM
Anxiety Shapes Expectations of Therapeutic Benefit in Phase I Trials for Patients With Advanced Cancer and Spousal Caregivers.

JCO oncology practice

Hlubocky FJ, Sher TG, Cella D, Wroblewski KE, Peppercorn J, Daugherty CK.
PMID: 33567241
JCO Oncol Pract. 2021 Feb;17(2):e101-e110. doi: 10.1200/OP.20.00646.

PURPOSE: Advanced cancer patients (ACP) hope to receive significant therapeutic benefit from phase I trials despite terminal disease and presumed symptom burdens. We examined associations between symptom burdens and expectations of therapeutic benefit for ACP and spousal caregivers (SC)...

Cite
Hlubocky FJ, Sher TG, Cella D, et al. Anxiety Shapes Expectations of Therapeutic Benefit in Phase I Trials for Patients With Advanced Cancer and Spousal Caregivers. JCO Oncol Pract. 2021;17(2):e101-e110doi: 10.1200/OP.20.00646.
Hlubocky, F. J., Sher, T. G., Cella, D., Wroblewski, K. E., Peppercorn, J., & Daugherty, C. K. (2021). Anxiety Shapes Expectations of Therapeutic Benefit in Phase I Trials for Patients With Advanced Cancer and Spousal Caregivers. JCO oncology practice, 17(2), e101-e110. https://doi.org/10.1200/OP.20.00646
Hlubocky, Fay J, et al. "Anxiety Shapes Expectations of Therapeutic Benefit in Phase I Trials for Patients With Advanced Cancer and Spousal Caregivers." JCO oncology practice vol. 17,2 (2021): e101-e110. doi: https://doi.org/10.1200/OP.20.00646
Hlubocky FJ, Sher TG, Cella D, Wroblewski KE, Peppercorn J, Daugherty CK. Anxiety Shapes Expectations of Therapeutic Benefit in Phase I Trials for Patients With Advanced Cancer and Spousal Caregivers. JCO Oncol Pract. 2021 Feb;17(2):e101-e110. doi: 10.1200/OP.20.00646. PMID: 33567241; PMCID: PMC8258142.
Copy Download .nbib Format: NLM
Trajectories of fear of cancer recurrence in young breast cancer survivors.

Cancer

Schapira L, Zheng Y, Gelber SI, Poorvu P, Ruddy KJ, Tamimi RM, Peppercorn J, Come SE, Borges VF, Partridge AH, Rosenberg SM.
PMID: 34614212
Cancer. 2021 Oct 06; doi: 10.1002/cncr.33921. Epub 2021 Oct 06.

BACKGROUND: Fear of cancer recurrence (FCR) is more intense in younger women. Because FCR is a powerful determinant of quality of life, identifying those at risk for persistently elevated FCR can inform timing of interventions.METHODS: A total of 965...

Cite
Schapira L, Zheng Y, Gelber SI, et al. Trajectories of fear of cancer recurrence in young breast cancer survivors. Cancer. 2021;doi: 10.1002/cncr.33921.
Schapira, L., Zheng, Y., Gelber, S. I., Poorvu, P., Ruddy, K. J., Tamimi, R. M., Peppercorn, J., Come, S. E., Borges, V. F., Partridge, A. H., & Rosenberg, S. M. (2021). Trajectories of fear of cancer recurrence in young breast cancer survivors. Cancer, . https://doi.org/10.1002/cncr.33921
Schapira, Lidia, et al. "Trajectories of fear of cancer recurrence in young breast cancer survivors." Cancer vol. (2021). doi: https://doi.org/10.1002/cncr.33921
Schapira L, Zheng Y, Gelber SI, Poorvu P, Ruddy KJ, Tamimi RM, Peppercorn J, Come SE, Borges VF, Partridge AH, Rosenberg SM. Trajectories of fear of cancer recurrence in young breast cancer survivors. Cancer. 2021 Oct 06; doi: 10.1002/cncr.33921. Epub 2021 Oct 06. PMID: 34614212.
Copy Download .nbib Format: NLM
Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors.

Cancer

Sella T, Poorvu PD, Ruddy KJ, Gelber SI, Tamimi RM, Peppercorn JM, Schapira L, Borges VF, Come SE, Partridge AH, Rosenberg SM.
PMID: 33886123
Cancer. 2021 Aug 15;127(16):2888-2894. doi: 10.1002/cncr.33596. Epub 2021 Apr 22.

BACKGROUND: The diagnosis and treatment of breast cancer can have profound effects on a young woman's family planning and fertility, particularly among women with hormone receptor-positive breast cancer.METHODS: The Young Women's Breast Cancer Study was a multicenter cohort of...

Cite
Sella T, Poorvu PD, Ruddy KJ, et al. Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors. Cancer. 2021;127(16):2888-2894doi: 10.1002/cncr.33596.
Sella, T., Poorvu, P. D., Ruddy, K. J., Gelber, S. I., Tamimi, R. M., Peppercorn, J. M., Schapira, L., Borges, V. F., Come, S. E., Partridge, A. H., & Rosenberg, S. M. (2021). Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors. Cancer, 127(16), 2888-2894. https://doi.org/10.1002/cncr.33596
Sella, Tal, et al. "Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors." Cancer vol. 127,16 (2021): 2888-2894. doi: https://doi.org/10.1002/cncr.33596
Sella T, Poorvu PD, Ruddy KJ, Gelber SI, Tamimi RM, Peppercorn JM, Schapira L, Borges VF, Come SE, Partridge AH, Rosenberg SM. Impact of fertility concerns on endocrine therapy decisions in young breast cancer survivors. Cancer. 2021 Aug 15;127(16):2888-2894. doi: 10.1002/cncr.33596. Epub 2021 Apr 22. PMID: 33886123; PMCID: PMC8351455.
Copy Download .nbib Format: NLM
Zanamivir aqueous solution in severe influenza: A global Compassionate Use Program, 2009-2019.

Influenza and other respiratory viruses

Wang-Jairaj J, Miller I, Joshi A, Jayabalan T, Peppercorn A, Zammit-Tabona P, Oliver A.
PMID: 34939702
Influenza Other Respir Viruses. 2021 Dec 22; doi: 10.1111/irv.12947. Epub 2021 Dec 22.

BACKGROUND: Zanamivir is a neuraminidase inhibitor effective against influenza A and B viruses. In 2009, GlaxoSmithKline (GSK) began clinical development of intravenous (IV) zanamivir and initiated a global Compassionate Use Program (CUP) in response to the evolving H1N1 global...

Cite
Wang-Jairaj J, Miller I, Joshi A, et al. Zanamivir aqueous solution in severe influenza: A global Compassionate Use Program, 2009-2019. Influenza Other Respir Viruses. 2021;doi: 10.1111/irv.12947.
Wang-Jairaj, J., Miller, I., Joshi, A., Jayabalan, T., Peppercorn, A., Zammit-Tabona, P., & Oliver, A. (2021). Zanamivir aqueous solution in severe influenza: A global Compassionate Use Program, 2009-2019. Influenza and other respiratory viruses, . https://doi.org/10.1111/irv.12947
Wang-Jairaj, Jie, et al. "Zanamivir aqueous solution in severe influenza: A global Compassionate Use Program, 2009-2019." Influenza and other respiratory viruses vol. (2021). doi: https://doi.org/10.1111/irv.12947
Wang-Jairaj J, Miller I, Joshi A, Jayabalan T, Peppercorn A, Zammit-Tabona P, Oliver A. Zanamivir aqueous solution in severe influenza: A global Compassionate Use Program, 2009-2019. Influenza Other Respir Viruses. 2021 Dec 22; doi: 10.1111/irv.12947. Epub 2021 Dec 22. PMID: 34939702.
Copy Download .nbib Format: NLM
Should all Crohn's patients receive prophylactic medication after surgical resection? No.

Inflammatory bowel diseases

Peppercorn MA.
PMID: 23282308
Inflamm Bowel Dis. 1995;1(2):162-4.

No abstract available.

Cite
Peppercorn MA. Should all Crohn's patients receive prophylactic medication after surgical resection? No. Inflamm Bowel Dis. 1995;1(2):162-4
Peppercorn, M. A. (1995). Should all Crohn's patients receive prophylactic medication after surgical resection? No. Inflammatory bowel diseases, 1(2), 162-4.
Peppercorn, M A. "Should all Crohn's patients receive prophylactic medication after surgical resection? No." Inflammatory bowel diseases vol. 1,2 (1995): 162-4.
Peppercorn MA. Should all Crohn's patients receive prophylactic medication after surgical resection? No. Inflamm Bowel Dis. 1995;1(2):162-4. PMID: 23282308.
Copy Download .nbib Format: NLM
Is there a genetic basis for clinical subsets of ulcerative colitis?.

Inflammatory bowel diseases

Peppercorn MA, Duerr RH.
PMID: 23282397
Inflamm Bowel Dis. 1995;1(3):234-5. doi: 10.1097/00054725-199509000-00012.

No abstract available.

Cite
Peppercorn MA, Duerr RH. Is there a genetic basis for clinical subsets of ulcerative colitis?. Inflamm Bowel Dis. 1995;1(3):234-5doi: 10.1097/00054725-199509000-00012.
Peppercorn, M. A., & Duerr, R. H. (1995). Is there a genetic basis for clinical subsets of ulcerative colitis?. Inflammatory bowel diseases, 1(3), 234-5. https://doi.org/10.1097/00054725-199509000-00012
Peppercorn, M A, and Duerr, R H. "Is there a genetic basis for clinical subsets of ulcerative colitis?." Inflammatory bowel diseases vol. 1,3 (1995): 234-5. doi: https://doi.org/10.1097/00054725-199509000-00012
Peppercorn MA, Duerr RH. Is there a genetic basis for clinical subsets of ulcerative colitis?. Inflamm Bowel Dis. 1995;1(3):234-5. doi: 10.1097/00054725-199509000-00012. PMID: 23282397.
Copy Download .nbib Format: NLM
Showing 1 to 12 of 53 entries